Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Summary of Asset Acquisition) (Details)

v3.22.0.1
Significant Transactions (Summary of Asset Acquisition) (Details)
Aug. 23, 2021
USD ($)
Purchase price allocated $ 7,500,000
Series A-2 Preferred Stock [Member]  
Purchase price allocated 1,760,000
Intangible Assets [Member]  
Purchase price allocated 4,300,000
Prepaid Expenses [Member]  
Purchase price allocated 1,440,000
Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]  
Purchase price allocated $ 7,500,000